Rasburicase biolsimilar(Paras Biopharmaceuticals Finland Oy)

N/A

Report date: 2024/01/15 13:51:58

Base Information

Drug NameRasburicase biolsimilar(Paras Biopharmaceuticals Finland Oy)

Drug Alias NamePB (CT)-4030

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme

Mechanisms of ActionUrate oxidases replacements

TargetsUrate oxidase

Therapy Area/IndicationsTumor Lysis Syndrome

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFinland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesParas Biopharmaceuticals Finland Oy

China Registration ClassN/A

Develop Information

Active CompaniesParas Biopharmaceuticals Finland Oy

Inactive CompaniesN/A

Active IndicationsTumor Lysis Syndrome

Inactive IndicationsN/A

Other Information

ATC CodeV03AF07